2100 WEST LOOP SOUTH, HOUSTON, TX
CNS Pharmaceuticals Enters $2.3M Securities Purchase Agreement
March 2026 Investor Presentation
Lynne Kelley Appointed Chief Medical Officer at CNS Pharmaceuticals
CFO Appointment - Steve O'Loughlin Named Chief Financial Officer
Rami Levin Appointed CEO of CNS Pharmaceuticals Effective January 1, 2026
CNS Pharmaceuticals Approves 2020 Equity Plan Amendments at Annual Meeting
Annual Report to Security Holders
Announces Reverse Stock Split
Q1
Amended Annual Report
FY 2025
Q3
Q2
FY 2024
Notice of Exempt Offering of Securities
Registration Statement for Securities Offered under a Shelf Registration
Registration Statement for Securities to be Offered to Employees
Prospectus filed pursuant to Rule 424(b)(5)
Prospectus filed pursuant to Rule 424(b)(4)
Effectiveness Notice
Amended Registration Statement for Securities
S-1
Additional Proxy Materials
Definitive Proxy Statement
PRE 14A
Statement of Changes in Beneficial Ownership
Amended Schedule 13G - Ownership Report
Schedule 13G - Ownership Report
Initial Statement of Beneficial Ownership
Correspondence
Submission Upload